Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

AORT - Artivion, Inc. Последние новости | Finranks

Home

/

AORT

A

Artivion, Inc. (AORT)

NYQ – Цена в реальном времени. Валюта: USD

28.48

+0.09 (0.32%)

Рынок открыт: Aug 12, 2026, 12:34 PM EDT

28.39

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update

Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update

Class A shares of the Alger Dynamic Opportunities Fund outperformed the S&P 500 Index during the second quarter of 2026. For the quarter, the portfolio's average long exposure was 88.77% and the average short exposure was -37.38%. Long positions Nebius Group, Astera Labs, Inc., and Western Digital Corporation were among the top contributors to performance.

Artivion Q2 Earnings Call Highlights

Artivion Q2 Earnings Call Highlights

Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.

Artivion Reports Second Quarter 2026 Financial Results

Artivion Reports Second Quarter 2026 Financial Results

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

Видео

No Data

There is no data to display

Пресс-релизы

Artivion Reports Second Quarter 2026 Financial Results

Artivion Reports Second Quarter 2026 Financial Results

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.